Pfizer announced on January 26th that its new generation of specific migraine treatment drug, Letaike (Rimezepam orally disintegrating tablets), has been approved by the National Medical Products Administration for the acute treatment of migraines in adults with or without aura.
According to Pfizer, this product is a calcitonin gene related peptide (CGRP) receptor antagonist using orally disintegrating tablet technology, which can effectively block the key pathways related to migraine onset, quickly and continuously alleviate headaches and related accompanying symptoms, and has no contraindications to cardiovascular diseases.
Jean Christophe Pointeau, Senior Vice President of Pfizer Global and President of Pfizer China, stated that Remdesipam Orally Invasive Tablets is the first next-generation migraine specific treatment drug to enter China. With CGRP as the treatment target and innovative Orally Invasive Technology, it solves the problem of insufficient drug efficacy and safety in the field of migraine treatment in the past.
"As the only CGRP receptor antagonist orally disintegrating tablets in the world to date, Rimezepam orally disintegrating tablets have brought new breakthroughs in the treatment of migraines, bringing new treatment options for Chinese clinical doctors and patients," he introduced.